AU2011269726B2 - Treatment of proliferative diseases - Google Patents

Treatment of proliferative diseases Download PDF

Info

Publication number
AU2011269726B2
AU2011269726B2 AU2011269726A AU2011269726A AU2011269726B2 AU 2011269726 B2 AU2011269726 B2 AU 2011269726B2 AU 2011269726 A AU2011269726 A AU 2011269726A AU 2011269726 A AU2011269726 A AU 2011269726A AU 2011269726 B2 AU2011269726 B2 AU 2011269726B2
Authority
AU
Australia
Prior art keywords
seq
nad1
nucleic acid
cells
plant defensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011269726A
Other languages
English (en)
Other versions
AU2011269726A1 (en
Inventor
Marilyn Anne Anderson
Mark Darren Hulett
Ivan Ka Ho Poon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BALMORAL AUSTRALIA Pty Ltd
Hexima Ltd
Original Assignee
BALMORAL AUSTRALIA Pty Ltd
Hexima Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BALMORAL AUSTRALIA Pty Ltd, Hexima Ltd filed Critical BALMORAL AUSTRALIA Pty Ltd
Publication of AU2011269726A1 publication Critical patent/AU2011269726A1/en
Assigned to HEXIMA LIMITED, BALMORAL AUSTRALIA PTY LTD reassignment HEXIMA LIMITED Amend patent request/document other than specification (104) Assignors: BALMORAL AUSTRALIA PTY LTD
Application granted granted Critical
Publication of AU2011269726B2 publication Critical patent/AU2011269726B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
AU2011269726A 2010-06-24 2011-06-23 Treatment of proliferative diseases Ceased AU2011269726B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35812610P 2010-06-24 2010-06-24
US61/358,126 2010-06-24
PCT/AU2011/000760 WO2011160174A1 (en) 2010-06-24 2011-06-23 Treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
AU2011269726A1 AU2011269726A1 (en) 2012-11-29
AU2011269726B2 true AU2011269726B2 (en) 2013-11-28

Family

ID=45370753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011269726A Ceased AU2011269726B2 (en) 2010-06-24 2011-06-23 Treatment of proliferative diseases

Country Status (12)

Country Link
US (1) US20120172313A1 (enExample)
EP (1) EP2585095A4 (enExample)
JP (1) JP2013530965A (enExample)
KR (1) KR20140003316A (enExample)
CN (1) CN103037888A (enExample)
AU (1) AU2011269726B2 (enExample)
CA (1) CA2803027A1 (enExample)
MX (1) MX2012014711A (enExample)
NZ (1) NZ603442A (enExample)
SG (1) SG186385A1 (enExample)
WO (1) WO2011160174A1 (enExample)
ZA (1) ZA201208389B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951057B1 (ko) 2011-02-07 2019-02-21 헥시마 리미티드 항병원성 물질로서 유용한 변경된 식물 데펜신
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3384938A1 (en) * 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012325676B2 (en) 2011-10-19 2016-07-21 Balmoral Australia Pty Ltd Novel plant defensins and use in the treatment of proliferative diseases
EP3303376A4 (en) * 2015-05-29 2019-01-23 Hexima Limited IN VIVO METHOD
CN111751345A (zh) * 2020-07-08 2020-10-09 深圳海关动植物检验检疫技术中心 一种苜蓿黄萎病菌活性检测方法
KR102371762B1 (ko) * 2020-12-29 2022-03-07 중앙대학교 산학협력단 Brca1 매개 nsd2 유비퀴틴화를 통한 세포 분화 및 세포사멸 조절 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002063011A1 (en) * 2001-02-08 2002-08-15 Hexima Ltd Plant-derived molecules and genetic sequences encoding same and uses therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339849B1 (en) * 2000-08-25 2006-10-18 BASF Plant Science GmbH PLANT POLYNUCLEOTIDES ENCODING NOVEL Na+ /H+ ANTIPORTERS
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
BRPI0916867A2 (pt) * 2008-08-05 2017-05-23 Hexima Ltd métodos para proteger uma planta de uma doença associada com infecção por um patógeno, e para identificar uma defensiva, uso de uma defensina de planta e um inibidor de proteinase ou uma forma precursora, planta geneticamente modificada ou progênie desta, e, defensiva

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002063011A1 (en) * 2001-02-08 2002-08-15 Hexima Ltd Plant-derived molecules and genetic sequences encoding same and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANAYA-LOPEZ, J.L. et al., Biotechnol Lett., 2006, Vol. 28 pages 1101-1108. *
LAY, F.T. and ANDERSON, M.A., Current Protein and Peptide Science, 2005, Vol. 6, pages 85-101. *

Also Published As

Publication number Publication date
KR20140003316A (ko) 2014-01-09
AU2011269726A1 (en) 2012-11-29
MX2012014711A (es) 2013-03-21
US20120172313A1 (en) 2012-07-05
SG186385A1 (en) 2013-01-30
EP2585095A4 (en) 2013-11-13
CN103037888A (zh) 2013-04-10
NZ603442A (en) 2013-09-27
ZA201208389B (en) 2013-06-26
JP2013530965A (ja) 2013-08-01
EP2585095A1 (en) 2013-05-01
WO2011160174A1 (en) 2011-12-29
CA2803027A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
Petersen et al. Peanut defensins: Novel allergens isolated from lipophilic peanut extract
US20120172313A1 (en) Treatment of proliferative diseases
Lay et al. Defensins-components of the innate immune system in plants
Kim et al. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines
Silva et al. Defensins: antifungal lessons from eukaryotes
Mackintosh et al. A gloverin-like antibacterial protein is synthesized in Helicoverpa armigera following bacterial challenge
Azmi et al. Analysis of structures, functions, and transgenicity of phytopeptides defensin and thionin: a review
Wang et al. Characterization of a desiccation-related protein in lily pollen during development and stress
SinghBains et al. Mitogenic and anti-proliferative activity of a lectin from the tubers of Voodoo lily (Sauromatum venosum)
Palavalli et al. Imbibition of soybean seeds in warm water results in the release of copious amounts of Bowman–Birk protease inhibitor, a putative anticarcinogenic agent
Monincova et al. Lasiocepsin, a novel cyclic antimicrobial peptide from the venom of eusocial bee Lasioglossum laticeps (Hymenoptera: Halictidae)
Chang et al. IbACP, a sixteen-amino-acid peptide isolated from Ipomoea batatas leaves, induces carcinoma cell apoptosis
US9540423B2 (en) Plant defensins and use in the treatment of proliferative diseases
Banerjee et al. Functional alteration of a dimeric insecticidal lectin to a monomeric antifungal protein correlated to its oligomeric status
Montesinos et al. Antimicrobial peptides for plant disease control. From discovery to application
Erlista et al. Proteome of monocled cobra (Naja kaouthia) venom and potent anti breast cancer peptide from trypsin hydrolyzate of the venom protein
Lee et al. Cell selectivity, mechanism of action and LPS-neutralizing activity of bovine myeloid antimicrobial peptide-18 (BMAP-18) and its analogs
Sen et al. Evaluation of anti-cancer potential of ragi bifunctional inhibitor (RBI) from Eleusine coracana on human chronic myeloid leukemia cells
Castilho et al. Isolation and characterization of four type 2 ribosome inactivating pulchellin isoforms from Abrus pulchellus seeds
TWI634210B (zh) 抑制熱休克蛋白質表現之胜肽及包含其之組成物
Kumari Discovery and application of cysteine-rich peptides from medicinal plants in drug development
Barkhuizen Mode of action studies of defensin peptides from native South African Brassicaceae species
NZ622284B2 (en) Novel plant defensins and use in the treatment of proliferative diseases
Kerenga Expression and characterization of highly divergent plant defensins
AL SOUHAIL Characterization, regulation and biophysical studies of immune-related peptides from Manduca sexta

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HULETT, MARK DARREN; POON, IVAN KA HO AND ANDERSON, MARILYN ANNE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired